



胃癌

召集人：陳仁浩 主任

胃癌診療指引

- 召集人: 陳仁浩主任


第十版

1

胃癌診療指引修訂

2025-01-19 修訂第九版	2026-01-09 修訂第十版
● 文獻指引更新	● 文獻指引更新 ● 胃癌臨床診療指引-1:局部病灶判定不可切除新增途徑:診斷性腹腔鏡手術

胃癌臨床診療指引-1




胃癌臨床診療指引-1

※註:

- 早期胃癌臨床分期為T1a，Dx可加做EUS檢查。
- Type I、Type IIa、Type IIb、Well differentiated $\leq 3\text{cm}$ ，可作ESD治療。
- (本院無ESD治療，建議轉院)。


胃癌臨床診療指引-2

初步評估	臨床診斷	臨床分期	主要治療	病理診斷	輔助治療	追蹤
------	------	------	------	------	------	----



胃癌臨床診療指引-3

初步評估	臨床診斷	臨床分期	主要治療	病理診斷	輔助治療	追蹤
------	------	------	------	------	------	----



胃癌臨床診療指引-4

初步評估	臨床診斷	臨床分期	主要治療	病理診斷	輔助治療	追蹤
------	------	------	------	------	------	----

	手術後1-2年內	手術後3-5年內
胸部影像學	每3-6個月	每6-12個月
腹部電腦斷層	每3-6個月	每6-12個月
腫瘤指標	每3-6個月	每6-12個月
胃鏡	每一年	每一年
營養監測B12、Iron (特別對於全胃切除者)	每3-6個月	每6-12個月

胃癌化療診療指引

Perioperative chemotherapy (Preferred)

化療系統 處方代碼	處方	藥名	劑量 (mg/m ²)	途徑	輸注時間	天數	頻率	療程數	文獻
Oxalip + FL		Oxaliplatin	85	IVD		D1			
		Leucovorin	400	IVD		D1			
		Fluorouracil	400	IVP		D1	Q2W	4 pre, 4 post	43
		Fluorouracil	1200	IVD	24h	D1-2			
Oxalip + FL		Oxaliplatin	85	IVD		D1			
		Leucovorin	200	IVD		D1	Q2W		1
		Fluorouracil	2600	IVD	48h	D1			
XELOX		Oxaliplatin	130	IVD		D1			
		Capecitabine	1000	PO	BID	D1-14	Q3W		2
FLOT		Oxaliplatin	85	IVD		D1			
		Leucovorin	200	IVD		D1			
		Fluorouracil	2600	IVD	24h	D1	Q2W	4 pre-op, 4 post-op	3
		Docetaxel	50	IVD		D1			

胃癌化療診療指引

Perioperative chemotherapy (Other)

化療系統 處方代碼	處方	藥名	劑量 (mg/m ²)	途徑	輸注時間	天數	頻率	療程數	文獻
	5-FU + Cisplatin(1)	Cisplatin	50	IVD		D1	Q2W	4 pre,4 post	4
		Fluorouracil	2000	IVD	48	D1			

胃癌化療診療指引

Preoperative chemoradiation

化療系統 處方代碼	處方	藥名	劑量 (mg/m ²)	途徑	輸注時間	天數	頻率	療程數	文獻
Oxalip + FL		Oxaliplatin	85	IVD		D1	Q2W	3 cycles with RT	6
		Leucovorin	200	IVD		D1			
		Fluorouracil	400	IVP	15min	D1			
		Fluorouracil	800	IVD	24h	D1-2			
Capecitabine + Oxaliplatin		Oxaliplatin	85	IVD		D1,15,29	QW	3 dose	7
		Capecitabine	625	PO	BID	D1-5		5	
5-FU + Cisplatin(1)		Cisplatin	75-100	IVD		D1,29	Q2W	35 day/cycle	8
		Fluorouracil	750-1000	IVD	24	D1-4,29-32			
5-FU + Cisplatin(2)		Cisplatin	15	IVD		D1-5	Q3W	2	9
		Fluorouracil	800	IVD	24h	D1-5			

胃癌化療診療指引

Preoperative chemoradiation

化療系統 處方代碼	處方	藥名	劑量 (mg/m ²)	途徑	輸注時間	天數	頻率	療程數	文獻
	Capecitabine + Cisplatin (preferred)	Cisplatin	30	IVD		D1	QW	5	10
		Capecitabine	800	PO	BID	D1-5			
	Paclitaxel + Carboplatin	Paclitaxel	50	IVD		D1	QW	5	12
		Carboplatin	AUC2	IVD		D1			

胃癌化療診療指引

Postoperative chemoradiation (For D2 LN dissection)

化療系統 處方代碼	處方	藥名	劑量 (mg/m ²)	途徑	輸注時間	天數	頻率	療程數	文獻
D006	XELOX	Oxaliplatin	130	IVD		D1	Q3W	8	13
		Capecitabine	1000	PO	BID	D1-14			
	Fluoropyrimidine +Oxaliplatin	Oxaliplatin	85	IVD		D1	Q2W		14
		Leucovorin	200	IVD		D1			
		Fluorouracil	2600	IVD	24h	D1			

胃癌化療診療指引

Postoperative chemoradiation (For less than D2 LN dissection)

化療系統 處方代碼	處方	藥名	劑量 (mg/m ²)	途徑	輸注時間	天數	頻率	療程數	文獻
D012 D012-1	5-FU	Leucovorin	400	IVD		D1	Q2W	2 cycles before and 4 cycles after chemoradiation	15
		Fluorouracil	400	IVP		D1			
		Fluorouracil	1200	IVD	24h	D1-2			
	5-FU	Fluorouracil	200-250	IVD	24h	D1-5	QW	5	15
	Capecitabine	Capecitabine	750-1000	PO	BID	D1-14	Q3W	1 cycle before and 2 cycles after chemoradiation	16-17
	Capecitabine	Capecitabine	625-825	PO	BID	D1-5	QW	5	16-17

胃癌化療診療指引

Postoperative chemotherapy (For patient who have undergone primary D2 LN dissection)

化療系統 處方代碼	處方	藥名	劑量 (mg/m ²)	途徑	輸注時間	天數	頻率	療程數	文獻
Oxalip + FL (preferred)		Oxaliplatin	85	IVD		D1	Q2W	3 pre,3 post	44
		Leucovorin	400	IVD		D1			
		Fluorouracil	400	IVP		D1			
		Fluorouracil	1200	IVD	24h	D1-2			
Capecitabine +Oxaliplatin		Oxaliplatin	130	IVD		D1	Q3W	8	45
		Capecitabine	1000	PO	BID	D1-14			
TS-1	TS-1	TS-1	40-60mg	PO	BID	28	42d/cycle	12 months	18-19
UFUR	UFUR	UFUR	300-350/d	PO		D1-28			47

胃癌化療診療指引

Postoperative chemotherapy (For patient who have undergone primary D2 LN dissection)

化療系統 處方代碼	處方	藥名	劑量 (mg/m ²)	途徑	輸注時間	天數	頻率	療程數	文獻
	Docetaxel+ TS-1	TS-1	40-60mg [#]	PO	BID	D1-14	Q3W	cycle1	22
		Docetaxel	40	IVD		D1	Q3W	Cycle 2-7 (6 cycles)	
		TS-1	40-60mg [#]	PO	BID	D1-14			
		TS-1	40-60mg [#]	PO	BID	D1-14	Q6W	For 1 year	

< 1.25 m², 40 mg; ≥ 1.25 to < 1.5 m², 50 mg; ≥ 1.5 m², 60 mg

胃癌化療診療指引

Chemoradiation for unresectable disease

化療系統 處方代碼	處方	藥名	劑量 (mg/m ²)	途徑	輸注時間	天數	頻率	療程數	文獻
	Oxalip + FL (preferred)	Oxaliplatin	85	IVD	2h	D1	Q2W	3 pre, 3 post	24
		Leucovorin	400	IVD	2h	D1			
		Fluorouracil	400	IVP	15min	D1			
		Fluorouracil	800	IVD	24h	D1-2			
	Capecitabine + Oxaliplatin (preferred)	Oxaliplatin	85	IVD	2h	D1,15,29	3 doses	5	20
		Capecitabine	625	PO	BID	D1-5	QW		
	Capecitabine + Cisplatin (preferred)	Cisplatin	30	IVD	2h	D1	QW	5	21
		Capecitabine	800	PO	BID	D1-5			

胃癌化療診療指引

Systemic therapy for metastatic or locally advanced cancer (1st-line)

化療系統 處方代碼	處方	藥名	劑量 (mg/m ²)	途徑	輸注時間	天數	頻率	療程數	文獻
	Trastuzumab+ chemotherapy	Trastuzumab	8mg/kg	IVD	1.5h	D1	Q3W	Cycle1	23
		Trastuzumab	6mg/kg	IVD	0.5h	D1	Q3W	After cycle1	
XELOX		Oxaliplatin	130	IVD	2h	D1	Q3W		25
		Capecitabine	1000	PO	BID	D1-14			
	Cisplatin+ 5-FU	Cisplatin	75-100	IVD	3h	D1	Q4W		26
		Fluorouracil	750-1000	IVD	24	D1-4			

胃癌化療診療指引

Systemic therapy for metastatic or locally advanced cancer (1st-line)

化療系統 處方代碼	處方	藥名	劑量 (mg/m ²)	途徑	輸注 時間	天數	頻率	療程數	文獻
D003	Nivolumab +XELOX	Nivolumab	360mg or 4.5mg/kg	IVD	30min	D1	Q3W	until disease progression	42
		Oxaliplatin	130	IVD	2h	D1			
		Capecitabine	1000	PO	BID	D1-14			
D001 D002	Nivolumab +FOLFOX	Nivolumab	240mg or 3mg/kg	IVD	30min	D1	Q2W	until disease progression	42
		Oxaliplatin	85	PO	2h	D1			
		Leucovorin	400	IVD	2h	D1			
		Fluorouracil	400	IVD	15min	D1			
		Fluorouracil	1200	IVD	24	D1-2			
	Pembrolizumab	Pembrolizumab	200mg	IVD	30min	D1	Q3W	Up to 2 years	48

胃癌化療診療指引

Systemic therapy for metastatic or locally advanced cancer (1st-line)

化療系統 處方代碼	處方	藥名	劑量 (mg/m ²)	途徑	輸注 時間	天數	頻率	療程數	文獻
D007	Cisplatin + FL	Cisplatin	50	IVD		D1			24
		Leucovorin	200	IVD		D1	Q2W		
		Fluorouracil	2000	IVD	24	D1			
	Cisplatin +Capecitabine	Cisplatin	80	IVD		D1	Q3W		25
		Capecitabine	1000	PO	BID	D1-14			
		Leucovorin	400	IVD	1.5	D1			
D007	Weekly high dose FL	Fluorouracil	400	IVD	15min	D1	QW		25
		Fluorouracil	2200	IVD	20h	D1			

胃癌化療診療指引

Systemic therapy for metastatic or locally advanced cancer (Other regimens)

化療系統 處方代碼	處方	藥名	劑量 (mg/m ²)	途徑	輸注時間	天數	頻率	療程數	文獻
D013 D013-1	Docetaxel +Cisplatin	Docetaxel	70-85	IVD		D1	Q3W		32-33
		Cisplatin	70-75	IVD		D1			
	FOLFIRI	Irinotecan	180	IVD	1.5h	D1	Q2W	12	49
		Leucovorin	400	IVD	1.5h	D1			
		Fluorouracil	2400	IVD	40h	D1			
D014	Paclitaxel+ 5-FU	Paclitaxel	45	IVD	3h	D1	QW	5	50
		Fluorouracil	1500	IVD	40h	D1			

胃癌化療診療指引

Systemic therapy for metastatic or locally advanced cancer (Other regimens)

化療系統 處方代碼	處方	藥名	劑量 (mg/m ²)	途徑	輸注時間	天數	頻率	療程數	文獻
D009 D009-1	mFOLFOX	Oxaliplatin	85	IVD	2	D1	Q2W	12	36
		Leucovorin	400	IVD	2	D1			
		Fluorouracil	400	IVP	15min	D1			
		Fluorouracil	1200	IVD	23	D1-2			
D015	Trastuzumab+ FOLFOX	Trastuzumab	6mg/kg (cycle1)	IVD	1.5h	D1	Q2W		51
		Trastuzumab	4mg/kg (cycle2~)	IVD	0.5h	D1			
		Leucovorin	400	IVD	2	D1			
		Fluorouracil	400	IVP	15min	D1			
		Fluorouracil	1200	IVD	23	D1-2			

胃癌化療診療指引

Systemic therapy for metastatic or locally advanced cancer (Other regimens)

化療系統 處方代碼	處方	藥名	劑量 (mg/m ²)	途徑	輸注時間	天數	頻率	療程數	文獻
D010	FL	Leucovorin	20	IVD	0.5	D1-4	Q4W	Cycle1,3,4	37
		Fluorouracil	425	IVD	0.5h	D1-4			
	TS-1	TS-1	40-60mg	PO	BID	28 days	42days /cycle	For 12 month	18-19

胃癌化療診療指引

Systemic therapy for metastatic or locally advanced cancer (2nd-line or subsequent therapy)

化療系統 處方代碼	處方	藥名	劑量 (mg/m ²)	途徑	輸注時間	天數	頻率	療程數	文獻
D008	Weekly paclitaxel	Paclitaxel	60	IVD	1h	D1	QW	1 st cycle	38
			60	IVD	0.5h	D1	QW	After 1 st cycle	
D011	Biweekly paclitaxel	Paclitaxel	120	IVD	1h	D1	Q2W		38
D005	Adriamycin	Doxorubicin	30	IVD	15mins	D1	Q2W		39
	UFUR	UFUR	300-350	PO				For 16 months	40
D004	Opdivo	Nivolumab	3mg/kg/day	IVD	0.5h	D1	Q2W	6	41

胃癌分期指引

胃癌分期類別定義		
腫瘤(T)		
TX	Primary tumor cannot be assessed	原發腫瘤無法評估
T0	No evidence of primary tumor	沒有原發腫瘤的證據
Tis	Carcinoma in situ: intraepithelial tumor without invasion of the lamina propria, high-grade dysplasia	黏膜內層, 上皮內腫瘤未侵犯黏膜固有層
T1a	Tumor invades the lamina propria or muscularis mucosae	腫瘤侵犯黏膜固有層或黏膜肌肉層
T1b	Tumor invades the submucosa	腫瘤侵犯黏膜下層
T2	Tumor invades the muscularis propria	腫瘤侵犯肌肉層
T3	Tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures	腫瘤穿透漿膜下結締組織但沒有侵犯腹膜臟層或周圍結構
T4a	Tumor invades the serosa (visceral peritoneum)	腫瘤穿透漿膜(腹膜臟層)
T4b	Tumor invades adjacent structures/organs	腫瘤直接侵犯周圍結構

胃癌分期指引

淋巴結(N)		
NX	Regional lymph node(s) cannot be assessed	區域淋巴結無法評估
N0	No regional lymph node metastasis	無區域淋巴結轉移
N1	Metastasis in one or two regional lymph nodes	1-2個區域淋巴結轉移
N2	Metastasis in three to six regional lymph nodes	3-6個區域淋巴結轉移
N3a	Metastasis in seven to 15 regional lymph nodes	7-15個區域淋巴結轉移
N3b	Metastasis in 16 or more regional lymph nodes	16個以上區域淋巴結轉移
轉移(M)		
M0	No distant metastasis	沒有遠處轉移
M1	Distant metastasis	遠處轉移

胃癌分期指引

臨床分期

病理分期

預後分期

Clinical T-N-M stage Grouping (cTNM)					
cTNM	N0	N1	N2	N3	M1
Tis	0				
T1	I	IIA	IIA	IIA	IVB
T2	I	IIA	IIA	IIA	IVB
T3	IIB	III	III	III	IVB
T4a	IIB	III	III	III	IVB
T4b	IVA	IVA	IVA	IVA	IVB

胃癌分期指引

臨床分期

病理分期

預後分期

Pathological stage groups(pTNM)						
pTNM	N0	N1	N2	N3a	N3b	M1
Tis	0					
T1	IA	IB	IIA	IIB	IIIB	IV
T2	IB	IIA	IIB	IIIA	IIIB	IV
T3	IIA	IIB	IIIA	IIIB	IIIC	IV
T4a	IIB	IIIA	IIIA	IIIB	IIIC	IV
T4b	IIIA	IIIB	IIIB	IIIC	IIIC	IV

胃癌分期指引

臨床分期	病理分期	預後分期
------	------	------

Post-Neoadjuvant therapy (ypTNM)					
ypTNM	N0	N1	N2	N3	M1
T1	I	I	II	II	IV
T2	I	II	II	III	IV
T3	II	II	III	III	IV
T4a	II	III	III	III	IV
T4b	III	III	III	III	IV



文獻

1. NCCN Clinical Practice Guidelines in Oncology ,Gastric cancer , **Version 3.2025**
2. Stephen R. Smalley , Jacqueline K. Benedetti , Daniel G. Haller et al. (2012) Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection J Clin Oncol, 30:2327-2333.
3. 國家衛生研究院 胃癌臨床診療指引2012年第1版
4. 日本胃癌診療指引第2004年版及2010年第4版

化療參考文獻

1. Al-Batran S-E, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. *J Clin Oncol* 2008;26:1435-1442.
2. Kim GM, Jeung HC, Rha SY, et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. *Eur J Cancer* 2012;48:518-526.
3. Al-Batran, S.E., et al., Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. *Lancet Oncol*, 2016. 17(12): p. 1697-1708.
4. Al-Batran S-E, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. *Lancet* 2019;393:1948-1957.
5. Conroy T, Galais MP, Raoul JL, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. *Lancet Oncol* 2014;15:305-314.
6. Javle MM, Yang G, Nwogu CE, et al. Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis. *Cancer Invest* 2009;27:193-200.
7. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. *J Clin Oncol* 2008;26:1086-1092.
8. Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFD 9102. *J Clin Oncol* 2007;25:1160-1168.
9. Lee SS, Kim SB, Park SI, et al. Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer. *Jpn J Clin Oncol* 2007;37:829-835.
10. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. *N Engl J Med* 2012;366:2074-2084.
11. Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. *Lancet Oncol* 2014;15:1389-1396.
12. Al-Batran S-E, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. *J Clin Oncol* 2008;26:1435-1442.



化療參考文獻

15. Leong T, Joon DL, Willis D, et al. Adjuvant chemoradiation for gastric cancer using epirubicin, cisplatin, and 5-fluorouracil before and after three-dimensional conformal radiotherapy with concurrent infusional 5-fluorouracil: a multicenter study of the Trans-Tasman Radiation Oncology Group. *Int J Radiat Oncol Biol Phys* 2011;79:690-695.
16. Jansen EP, Boot H, Saunders MP, et al. A phase I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer. *Int J Radiat Oncol Biol Phys* 2007;69:1424-1428.
17. Lee HS, Choi Y, Hur WJ, et al. Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation with capecitabine. *World J Gastroenterol* 2006;12:603-607.
18. Shinichi Sakuramoto, Mitsuru Sasako, Toshiharu Yamaguchi et al: Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine. *N Engl J* 2007 vol.357.1810-1820
19. Jen-Shi Chen, Yee Chao, Ruey-Kuen Hsieh et al: A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan. *Cancer Chemother Pharmacol* .17 August 2010
20. Javle MM, Yang G, Nwogu CE, et al. Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis. *Cancer Invest* 2009;27:193-200.
21. Lee SS, Kim SB, Park SI, et al. Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer. *Jpn J Clin Oncol* 2007;37:829-835.
22. Yoshida K, Koda Y, Kochi M, et al. Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial. *Clinical Oncology* 2019; 37:1296-1304.
23. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastroesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 2010;376:687-697.
24. Conroy T, Galais MP, Raoul JL, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. *Lancet Oncol* 2014;15:305-314
25. Kim GM, Jeung HC, Rha SY, et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. *Eur J Cancer* 2012;48:518-526.
26. Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. *Ann Oncol* 2009;20:1667-1673.
27. Al-Batran S-E, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. *J Clin Oncol* 2008;26:1435-1442.
28. Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. *Ann Oncol* 2009;20:666-673.



化療參考文獻

29. Lin YC, Liu HE, et al. Clinical benefit and response in patients with gastric cancer to weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and leucovorin (LV). *Anticancer Res.* 1999;19(6C):5615-20
31. Ilson DH, Forastiere A, Arquette M, et al. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. *Cancer J* 2000;6:316-323.
32. Ajani JA, Fodor MB, Tjuland SA, et al. Phase II multiinstitutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. *J Clin Oncol* 2005;23:5660-5667.
33. Kim JY, Do YR, Park KU, et al. A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer. *Cancer Chemother Pharmacol* 2010;66:31-36.
34. Se Hoon Park, Woon Kee Lee, Min Chung, et al. (2006). Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil. *Anti-Cancer Drugs*, 17:225-229.
35. Gun Hi Kang, M.D., Gwang Sil Kim, M.D., Hyo Rak Lee, M.D., et al. (2008). A Phase II Trial of Paclitaxel, 5-fluorouracil (5-FU) and Cisplatin in Patients with Metastatic or Recurrent Gastric cancer. *Cancer Res Treat*, 40:106-110.
36. Salah-Eddin Al-Batran, Joerg Thomas Hartmann, Stephan Probst et al. (2008) Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie. *J Clin Oncol*, 26:1435-1442.
37. Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. *J Clin Oncol* 2012;30:2327-2333.
38. Hironaka S, Ueda S, Yasui H, et al. (2013). Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 Trial. *J Clin Oncol*, 31:4438-4444.
39. Wöhrer SS, Raderer M, Hejna M et al, Palliative chemotherapy for advanced gastric cancer. *Ann Oncol*, 2004 Nov;15(11):1585-95.
40. T.Nakajima, T.Kinoshita, A. Nashimoto et al: Randomized controlled trial of adjuvant uracil –tegafur versus surgery alone for resectable, locally advanced gastric cancer. *British Journal of Surgery* 2007, vol. 94:1468-1476.
41. Kang YK, Boku N, Satoh T, et al, "Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo controlled, phase 3 trial," *Lancet*. 2017 Dec 2;390(10111):2461-2471.
42. M. Moehler, K. Shitara, M. Garrido, et al, "Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study," *Annals of Oncology*, Volume 31, Suppl 4, 2020, pp. S1191

化療參考文獻

43. Enzinger PC, Burtneß BA, Niedzwiecki D, et al. CALGB 80403 (Alliance)/E1206: a randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal junction cancers. *J Clin Oncol* 2016;34:2736-2742.
44. Enzinger PC, Burtneß B, Hollis D, et al. CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer [abstract]. *J Clin Oncol* 2010;28 (Suppl 15):Abstract 4006.
45. Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC):5-year follow-up of an open-label, randomised phase 3 trial. *Lancet Oncol* 2014; 15:1389-1396.
47. Product Information: UFUR Capsule. tegafur, uracil oral capsules. 2015.
48. Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. *JAMA Oncol* 2018;4:e180013.
49. Guimbaud, R., Louvet, C., Ries, P., et al. (2014). Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 32(31), 3520–3526. <https://doi.org/10.1200/JCO.2013.54.1011>
50. Ajani, J. A., Winter, K., Okawara, G. S., Donohue, J. H., Pisters, P. W., Crane, C. H., Greskovich, J. F., Anne, P. R., Bradley, J. D., Willett, C., & Rich, T. A. (2006). Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 24(24), 3953–3958. <https://doi.org/10.1200/JCO.2006.06.4840>
51. Soularue, É., Cohen, R., Tournigand, C., Zaanan, A., Louvet, C., Bachet, J. B., Hentic, O., Samalin, E., Chibaudel, B., de Gramont, A., André, T., & for GERCOR (2015). Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study. *Bulletin du cancer*, 102(4), 324–331. <https://doi.org/10.1016/j.bulcan.2014.08.001>

